Special Issue

Recent Advancements in the Development of Antiprotozoal Agents

Message from the Guest Editors

Protozoa from different genera cause infections that engender several prominent and grave diseases in humans. Owing to their widespread presence and major impact in developing countries, most of the infections are categorized as Neglected Tropical Diseases. However, the distribution of such diseases has dramatically changed in recent years, with many of them being reported in other parts of the world; thus, they have become a relevant global threat for human health. On the other hand, chemotherapy has always relied on a very few and primarily old drugs, which have major limitations including low efficacy and relevant toxicity; their use so far has been justified by the lack of effective alternatives. Hence, increasing efforts have been devoted to find alternatives of the existing chemotherapy drugs in the last decade. This Special Issue aims to collate papers that underscore the latest findings in the search of antiprotozoal agents with various mechanisms of action and the discovery of novel biological targets. We welcome submissions of both original research articles and reviews.

Guest Editors

Dr. Francesco Saccoliti

Dipartimento di Scienze della Vita, della Salute e delle Professioni Sanitarie, Università degli Studi "Link Campus University", Via del Casale di S. Pio V, 44, 00165 Rome, Italy

Dr. Alessandro Giraudo

Department of Pharmaceutical Sciences, University of Milan, via Mangiagalli 25, 20133 Milano, Italy

Deadline for manuscript submissions

25 September 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/186667

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

